glp 1 agonists and depression Insights into a possible role of glucagon-like peptide-1 receptor in the treatment of | Pharmacological Reports Investigating the association between GLP-1

Furthermore, they also found that 'a balanced dual agonist in mice engineered to lack GLP-1 receptors still induced weight loss, proving that the compounds were not causing weight loss purely by targeting GLP-1' (Molteni, Chen)

doi: 10.1080/14656566.2019.1571040 [DOI] [PubMed] [Google Scholar] 122

Do GLP-1 medications make you tired

Preclinical studies have identified that GLP-1 analogs such as exendin-4 and GLP-1RAs have direct anti-atherosclerotic and anti-inflammatory effects that may contribute to their cardio- and neuroprotective nature.[42] GLP-1RAs can also directly interact with cardiomyocytes, inducing receptor-mediated ischemic conditioning that decreases myocardial infarct size in test animals receiving GLP-1RAs.[43] Similar effects were noted in rodent brains, with liraglutide reducing cerebral infarct volume in rats.[42] Randomized clinical trials (RCTs) also identified that exenatide similarly reduced myocardial infarct size and liraglutide reduced the resulting necrotic area in human patients following a MI.[43] This may account for the reduced need for coronary revascularization in patients on GLP-1RAs.[12] Despite the findings of overall improvements to composite cardiovascular outcomes, GLP-1RAs showed a non-significant trend toward reducing MI risk and did not affect rates of hospitalization for unstable angina in patients with diabetes.[12] These agents tend to have a stronger effect on stroke reduction in such patients, highlighting the complexity and variability of cardiovascular disease and its sequelae

Similarly, IL-6 levels in the control, HG, 50 nM liraglutide, and 100 nM Liraglutide groups were 135.2, 256.8, 191.6, and 172.9 pg/mL, respectively